Mouse IgG1e3 ControlInvivoGen Kontakt z doradcą
Anti-β-Gal-mIgG1e3 InvivoFit™ is a recombinant monoclonal antibody (mAb) comprising the variable region of the hybridoma-derived mAb Mouse IgG2a Control (clone: T9C6) that targets E. coli β-galactosidase (β-Gal).
This mAb does not react with murine proteins.
Anti-β-Gal-mIgG1e3 InvivoFit™ features the murine IgG1e3 isotype that contains a point mutation D265A (a replacement of aspartic acid by alanine at position 265), resulting in the complete loss of cytolytic effector functions [1, 2].
This mAb is provided as an isotype control for use with InvivoGen's IgG1e3 antibodies in the mouse anti-mouse mAbs collection.
It has been produced in CHO cells and purified by affinity chromatography with protein G.
Key features of Anti-β-Gal-mIgG1e3 InvivoFit™:
- Sequence is 100% murine
- Guaranteed sterile, endotoxin level < 1 EU/mg
- Suitable for parenteral delivery in mice (azide-free)
- Low aggregation < 5%
- Produced in both animal-free facilities and defined media
- Yamazaki T. et al., 2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.
- Baudino L. et al., 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 181(9):6664-9.